Key Highlights
•
A new, brief rating scale for schizophrenia symptoms, called the BE-PSD-V2.0, has been validated and corresponds well with established, more complex scales. This means doctors can assess symptoms more quickly and easily, while still using the same clinical benchmarks they are familiar with.
Source →
•
A study found that most relapses in relapsing-remitting multiple sclerosis (RRMS) do recover, but the process can take up to a year, challenging the idea that disability progression measured at 3 or 6 months is always permanent. This finding suggests that recovery from MS attacks is slower and more complex than previously thought, which could influence how treatment success is measured in clinical trials.
Source →
•
A new screening strategy for Alzheimer’s disease, combining a brief cognitive test with a blood test for a protein called p-tau217, has been successfully implemented in a community health screening in China. This practical approach could help identify people at risk for Alzheimer’s earlier, especially in regions with limited healthcare resources, aiding in clinical trial recruitment and better care planning.
Source →
•
Research shows that variability in a person’s normal breathing patterns between seizures is linked to more severe drops in oxygen levels after a major convulsive seizure. Understanding this connection could help identify patients at higher risk for dangerous post-seizure complications, allowing for closer monitoring and potentially life-saving interventions.
Source →
•
A study in sheep found that exposure to male hormones (androgens) before birth can lead to changes in sexual behavior later in life. This animal research provides important clues about how early hormonal environments can permanently shape brain development and behavior, which may have implications for understanding similar processes in humans.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
